Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
Authors' conclusion
ncs-DMARDs alone or combined with conventional therapy might be an optimal and promising treatment for stabilising or improving ILD in patients with RA-ILD.
Study context
- Population
- Patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD)
- Participants
- 1,315 patients17 studies
- Comparison
- Non-conventional synthetic DMARDs, after vs before treatment
- Outcome
- FVC, FEV1 and DLCO after ncs-DMARD treatment vs baseline (pooled)
Methodological detailsDatabases: PubMed, EMBASE, Cochrane Library, Web of Science, inception to 1 June 2022
- Databases: PubMed, EMBASE, Cochrane Library, Web of Science, inception to 1 June 2022
Pooled result
As reported in the abstract
- No significant changes in forced vital capacity (FVC)
- p=0.36
- No significant changes in FEV1
- p=0.96
- No significant changes in DLCO
- p=0.46
Further pooled results
FVC change, rituximab subgroup
| MD (95% CI) | P value | ||
|---|---|---|---|
| RituximabFVC obviously increased in rituximab subgroup | −4.62 (−8.90 to −0.33) | P = 0.03 | |
| −10−505Difference (linear scale) |
High-resolution CT non-progression rate (pooled)
- High-resolution CT non-progression rate
- 0.792 (95% CI 0.746 to 0.834, p=0.015)
Fatality rate due to ILD progression (pooled)
- Fatality rate due to ILD progression
- 0.049 (95% CI 0.035 to 0.065, p=0.000)
Original publication
Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. RMD Open. Published 29 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →